A Phase 3 interventional study of Fulvestrant and Anastrozole in Breast Cancer, sponsored by AstraZeneca. Completed at 85 sites in 12 countries. Open to female participants. Per ClinicalTrials.gov, last updated 2012-08-01.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.
Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 14th largest by enrollment of the 94 interventional ones that give a count, is one of 10 that started in 2004, is one of 21 in phase 3, and was the 16th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19–80 · Women only
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
University of California, Irvine · Sites in United States
Ages 18+
Prof. Wolfgang Janni · Sites in Germany, Switzerland
Ages 18+ · Women only
Royal Marsden NHS Foundation Trust · Sites in France, United Kingdom
Ages 18+
By country, each count listing its studies:
Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, fulvestrant is the treatment under test here. Read study by study →
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 63 · Phase 3 21 · Phase 4 4
First in 1997; this study’s year is marked. 10 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 514 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 71 across the 94 interventional studies. Of the 55 that completed or were terminated, 34 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 95 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 28th largest by enrollment of the 125 interventional ones that give a count, is one of 14 that started in 2004, is one of 46 in phase 3, and was the 17th registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
7 of the studies testing fulvestrant in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01953588Phase 3Alliance for Clinical Trials in OncologyFulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | 2027-04-01 |
| NCT07163481Hunan Cancer HospitalA Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors | 2026-12 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT00585507Beth Israel Deaconess Medical CenterEfficacy and Safety of 500mg of Fulvestrant | 2027-03-15 |
| NCT05319873Jonsson Comprehensive Cancer CenterRibociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 95 studies testing fulvestrant in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy of anastrozole monotherapy versus maximal oestrogen blockade with combinated therapy of fulvestrant and anastrozole compared with in treatment of hormone receptor positive women with first relapse of breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anastrozole
Drug: Anastrozole
Anastrozole + Fulvestrant
Drug: Fulvestrant · Drug: Anastrozole
intramuscular injection 250 mg loading dose (LD) regimen
Also known as: Faslodex, ZD9238
1 mg oral tablet
Also known as: Arimidex, ZD1033
Time to Progression (TTP)
RECIST (Response Evaluation Criteria in Solid Tumours) assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009. TTP, time in months to worsen 'progression' according to RECIST criteria. (RECIST is a set of published rules that define when cancer patients improve "respond", stay the same "stable"or worsen "progression" during treatments.
Time frame: RECIST assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009
Percentage of Evaluable Participants With Objective Response Rate (ORR)
No. of patients who were objective responders over the no. of patients evaluable for response x100. An objective responder = a patient whose best response is either CR (disappearance of all lesions) or PR (\>= 30% shrinkage in the sum of the longest diamemeters of the measurable lesions + no new lesions + no progression of non-measurable lesions)
Time frame: RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009
Percentage of Clinical Benefit Rate (CBR) Responders
No. of patients who were clinical benefit responders over the no. of randomised patients x100. A clinical benefit responder = a patient whose best response is CR, PR or SD\>=24 weeks (where a best response of SD = no new lesions and for existing lesions; neither suffient shrinkage to count as PR nor sufficient growth to count as progression)
Time frame: RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009
Duration of Response (DoR)
Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are objective responders
Time frame: RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009
Duration of Clinical Benefit (DoCB)
Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are clinical benefit responders
Time frame: RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009
Time to Treatment Failure (TTF)
Time from randomisation until the date of discontinuation of randomised treatment for any reason
Time frame: From randomisation until data cut-off on 30th April 2009
Overall Survival (OS)
Overall survival is equivalent to time to death. Time from randomisation until the date of death
Time frame: All deaths occurring between randomisation and data cut-off on 30th April 2009 are included.
258 patients were randomised to Fulvestrant + Anastrozole and 256 patients were randomised to Anastrozole. In each treatment group, there were 2 patients who did not receive any trial therapy and so have been excluded from the safety summaries.
| Milestone | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|
| Started | 258 | 256 |
| Completed | 91 | 84 |
| Not completed | 167 | 172 |
| Withdrew: Withdrawal by subject | 7 | 7 |
| Withdrew: Adverse event | 13 | 6 |
| Withdrew: Protocol violation | 6 | 5 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Disease progression | 97 | 105 |
| Withdrew: Still ongoing at data cut-off | 41 | 46 |
| Withdrew: Withdrawn due to osteoporosis | 1 | 0 |
| Withdrew: Prematurely discontinued | 1 | 0 |
RECIST (Response Evaluation Criteria in Solid Tumours) assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009. TTP, time in months to worsen 'progression' according to RECIST criteria. (RECIST is a set of published rules that define when cancer patients improve "respond", stay the same "stable"or worsen "progression" during treatments.
| months | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|
| Time to Progression (TTP) | 10.8 (0 to 49.31) | 10.2 (0 to 54.34) |
No. of patients who were objective responders over the no. of patients evaluable for response x100. An objective responder = a patient whose best response is either CR (disappearance of all lesions) or PR (\>= 30% shrinkage in the sum of the longest diamemeters of the measurable lesions + no new lesions + no progression of non-measurable lesions)
| Percentage of evaluable participants | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|
| Percentage of Evaluable Participants With Objective Response Rate (ORR) | 31.8 | 33.6 |
No. of patients who were clinical benefit responders over the no. of randomised patients x100. A clinical benefit responder = a patient whose best response is CR, PR or SD\>=24 weeks (where a best response of SD = no new lesions and for existing lesions; neither suffient shrinkage to count as PR nor sufficient growth to count as progression)
| Percentage of participants | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|
| Percentage of Clinical Benefit Rate (CBR) Responders | 55.0 | 55.1 |
Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are objective responders
| months | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|
| Duration of Response (DoR) | 22.3 (5.55 to 46.95) | 18.2 (7.20 to 49.77) |
Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are clinical benefit responders
| months | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|
| Duration of Clinical Benefit (DoCB) | 18.5 (1.64 to 46.95) | 18.1 (5.19 to 54.34) |
Time from randomisation until the date of discontinuation of randomised treatment for any reason
| months | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|
| Time to Treatment Failure (TTF) | 12.4 (0 to 46.95) | 11.4 (0 to 54.34) |
Overall survival is equivalent to time to death. Time from randomisation until the date of death
| months | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|
| Overall Survival (OS) | 37.8 (0.07 to 61.86) | 38.2 (0.13 to 60.39) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fulvestrant + Anastrozole | — | 40/256 (15.6%) | 161/256 (62.9%) |
| Anastrozole | — | 45/254 (17.7%) | 178/254 (70.1%) |
| Event | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|
| General Physical Health DeteriorationGeneral disorders | 0/256 | 3/254 |
| Cardiac FailureCardiac disorders | 3/256 | 1/254 |
| PneumoniaInfections and infestations | 3/256 | 2/254 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/256 | 2/254 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 3/256 | 0/254 |
| Pericardial EffusionCardiac disorders | 0/256 | 2/254 |
| VertigoEar and labyrinth disorders | 0/256 | 2/254 |
| NauseaGastrointestinal disorders | 2/256 | 2/254 |
| Chest PainGeneral disorders | 1/256 | 2/254 |
| PainGeneral disorders | 0/256 | 2/254 |
| Event | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|
| FatigueGeneral disorders | 27/256 | 33/254 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 30/256 | 27/254 |
| NauseaGastrointestinal disorders | 23/256 | 27/254 |
| Hot flushVascular disorders | 21/256 | 19/254 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 8/256 | 20/254 |
| Back painMusculoskeletal and connective tissue disorders | 11/256 | 15/254 |
| ConstipationGastrointestinal disorders | 15/256 | 12/254 |
| DiarrhoeaGastrointestinal disorders | 15/256 | 13/254 |
| Urinary tract infectionInfections and infestations | 14/256 | 8/254 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/256 | 13/254 |
| Age Continuous(Years) | Fulvestrant + Anastrozole | Anastrozole | Total |
|---|---|---|---|
| Mean | 65.2 ± 9.6 | 63.4 ± 10.3 | 64.3 ± 10.0 |
| Sex: Female, Male(Participants) | Fulvestrant + Anastrozole | Anastrozole | Total |
|---|---|---|---|
| Female | 258 | 256 | 514 |
| Male | 0 | 0 | 0 |
The record gives a start of Jan 2004, a primary completion of Apr 2009 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fulvestrant